JP2012144480A - Oral cavity composition - Google Patents

Abstract

PROBLEM TO BE SOLVED: To provide an oral cavity composition containing a relatively large amount of glycyrrhizic acid or salt thereof with respect to cetyl pyridinium chloride, and capable of restraining an bactericidal activity of the cetyl pyridinium chloride from getting low, even when used under the presence of saliva.SOLUTION: The oral cavity composition contains (i) the cetyl pyridinium chloride, (ii) the glycyrrhizic acid or the salt thereof, (iii) at least one kind of alcohol selected from the group constituted of propylene glycol, 1,3-butylene glycol and ethanol, and (iv) 1-menthol, and a mass ratio (glycyrrhizic acid or salt thereof/cetyl pyridinium chloride) of the glycyrrhizic acid or the salt thereof to the cetyl pyridinium chloride is 1 or more, in the oral cavity composition.

Description

  The present invention relates to an oral composition.

  Cetylpyridinium chloride, a cationic fungicide, has a high bactericidal activity against oral bacteria, adsorbs to the oral mucosa and tooth surface, inhibits the adsorption of oral bacteria on the tooth surface, and suppresses the formation of plaque Are known. For this reason, it is conventionally mix | blended with the composition for oral cavity as a disinfectant.

  Glycyrrhizic acid is a component contained in licorice root. Glycyrrhizic acid or a salt thereof is known to have an anti-inflammatory effect. It is also a substance exhibiting sweetness and is known to be useful for improving taste. For this reason, it is conventionally blended in an oral composition as an anti-inflammatory agent (or sweetener).

  And the composition for oral cavity containing a cetyl pyridinium chloride and glycyrrhizic acid or its salt is already known (for example, refer patent document 1). As described above, cetylpyridinium chloride is blended in the oral composition as a fungicide and glycyrrhizic acid or a salt thereof as an anti-inflammatory agent.

JP 2007-008831 A

  As described above, oral compositions containing cetylpyridinium chloride and glycyrrhizic acid or salts thereof are known. In addition to oral compositions, cosmetics (especially skin cosmetics) and external preparations are known in which cetylpyridinium chloride and glycyrrhizic acid are blended. In such various compositions, cetylpyridinium chloride has a bactericidal effect, and glycyrrhizic acid or a salt thereof has an anti-inflammatory effect.

  When the present inventors examined in more detail the bactericidal effect in a composition containing cetylpyridinium chloride and glycyrrhizic acid or a salt thereof, a composition containing a relatively large amount of glycyrrhizic acid or a salt thereof with cetylpyridinium chloride When a product (particularly a composition having a mass ratio of glycyrrhizic acid or a salt thereof to cetylpyridinium chloride or a salt thereof (glycyrrhizic acid or a salt thereof / cetylpyridinium chloride) of 1 or more) is used in the presence of saliva, It has been found that the ability to sterilize oral bacteria of the human body decreases. In other words, since cosmetics and external preparations are not usually used in the presence of saliva, even if a relatively large amount of glycyrrhizic acid or a salt thereof is added to cetylpyridinium chloride, the bactericidal activity does not decrease. However, since the composition for oral cavity is applied in the oral cavity, it is usually used in the presence of saliva, and it has been found that there is a problem that the sterilizing power can be reduced.

  Therefore, the present invention is to provide an oral composition in which a decrease in bactericidal power of cetylpyridinium chloride is suppressed even when glycyrrhizic acid or a salt thereof is contained in a relatively large amount with respect to cetylpyridinium chloride. And

  As a result of intensive studies, the present inventors have surprisingly found (i) cetylpyridinium chloride, (ii) glycyrrhizic acid or a salt thereof, and (iii) propylene glycol, 1,3-butylene glycol, and ethanol. A composition containing at least one alcohol selected from the group consisting of (iv) l-menthol and containing a relatively large amount of glycyrrhizic acid or a salt thereof with respect to cetylpyridinium chloride, and the presence of saliva Even when used below, it has been found that the decrease in bactericidal power of cetylpyridinium chloride is suppressed, and further improvements have been made to complete the present invention.

That is, this invention includes the composition for oral cavity as described in the following items, for example.
Item 1.
(Ii) cetylpyridinium chloride, (ii) glycyrrhizic acid or a salt thereof, (iii) at least one alcohol selected from the group consisting of propylene glycol, 1,3-butylene glycol, and ethanol, and (iv) l- Contains menthol,
The composition for oral cavity whose mass ratio (Glycyrrhizic acid or its salt / cetylpyridinium chloride) of glycyrrhizic acid or its salt with respect to cetylpyridinium chloride is 1 or more.
Item 2.
Item 2. The oral cavity composition according to Item 1, comprising 0.05 to 0.5 mass% of (i) and 0.05 to 0.5 mass% of (ii).
Item 3.
Item 3. The oral composition according to Item 1 or 2, which contains 1 to 30% by mass of (iii) and 0.01 to 2% by mass of (iv).

  An oral composition containing cetylpyridinium chloride and glycyrrhizic acid or a salt thereof is used so that a mass ratio of glycyrrhizic acid or a salt thereof to cetylpyridinium chloride (glycyrrhizic acid or a salt thereof / cetylpyridinium chloride) is 1 or more In this case, when the sterilizing power (bactericidal effect) of cetylpyridinium chloride is reduced, (i) cetylpyridinium chloride, (ii) glycyrrhizic acid or a salt thereof, (iii) propylene glycol, 1, 3 -Butylene glycol, and at least one alcohol selected from the group consisting of ethanol, and (iv) 1-menthol mass ratio of glycyrrhizic acid or a salt thereof to cetylpyridinium chloride (glycyrrhizic acid or a salt / salt thereof) Cetylpyridinium) is 1 If the oral composition is above, lowering of bactericidal power of cetyl pyridinium chloride has (bactericidal effect) (is reduced) by the suppression.

  Hereinafter, the present invention will be described in more detail.

The composition for oral cavity of the present invention is
(I) cetylpyridinium chloride,
(Ii) glycyrrhizic acid or a salt thereof,
(Iii) at least one alcohol selected from the group consisting of propylene glycol, 1,3-butylene glycol, and ethanol, and (iv) 1-menthol. The mass ratio of glycyrrhizic acid or a salt thereof to cetylpyridinium chloride (glycyrrhizic acid or a salt thereof / cetylpyridinium chloride) is 1 or more.

  Cetylpyridinium chloride is a cationic bactericidal agent contained in a quaternary ammonium compound, and is a known substance widely used for the purpose of sterilizing oral bacteria in the field of oral compositions. The content of cetylpyridinium chloride in the oral composition of the present invention is preferably 0.05 to 0.5% by mass, more preferably 0.05 to 0.3% by mass, and still more preferably 0.1 to 0. 3% by mass.

  In addition, oral bacteria are known to cause periodontal disease and caries, and examples include Porphyromonas gingivalis, Tannerela forsythia, Streptococcus mutans and the like.

  Glycyrrhizic acid is an active ingredient contained in licorice root, and is known to have anti-inflammatory action. Further, glycyrrhizic acid salts are also known to have anti-inflammatory effects. The salt of glycyrrhizic acid contained in the oral composition of the present invention is not particularly limited as long as the effects of the present invention are not impaired, and examples thereof include potassium salts, sodium salts, ammonium salts and the like. Specific examples include dipotassium glycyrrhizinate, disodium glycyrrhizinate, and monoammonium glycyrrhizinate. Of these, dipotassium glycyrrhizinate is preferable. The content of glycyrrhizic acid or a salt thereof in the oral composition of the present invention is preferably 0.05 to 0.5% by mass, more preferably 0.1 to 0.5% by mass, and still more preferably 0.3 to 0.5% by mass.

  The alcohol contained in the oral composition of the present invention is at least one selected from the group consisting of propylene glycol, 1,3-butylene glycol, and ethanol. That is, these three types of alcohols can be used alone or in combination of two or more. The ratio of these three alcohols when combined can be set as appropriate. Of these, propylene glycol is preferred. When the three kinds of alcohols are used in combination, there is no particular limitation, but propylene glycol is preferably the main component of alcohol (50% or more of the total alcohol). It is particularly preferred to use propylene glycol alone.

  The content of the alcohol in the oral composition of the present invention is not particularly limited, but the total content of the three alcohols is preferably 1 to 30% by mass, more preferably 2 to 25% by mass, Preferably it is 4-20 mass%, More preferably, it is 5-20 mass%.

  The oral composition of the present invention further contains l-menthol. As l-menthol used in the present invention, for example, synthesized l-menthol or l-menthol extracted from natural products can be used, and peppermint oil, spearmint oil, mint oil containing l-menthol It is also possible to use natural essential oils such as natural perfumes and mixed fragrances containing l-menthol.

  The content of 1-menthol in the oral composition of the present invention is preferably 0.01 to 2% by mass, more preferably 0.01 to 1% by mass, still more preferably 0.02 to 0.5% by mass, More preferably, it is 0.03-0.3 mass%. In addition, content of 1-menthol means content of 1-menthol contained in the said extract or natural essential oil, when using an extract or natural essential oil.

  The more the content of (ii) glycyrrhizic acid or a salt thereof relative to the content of (i) cetylpyridinium chloride in the oral composition, the more remarkable the bactericidal activity decreases. In other words, the greater the mass ratio of the amount of glycyrrhizic acid or its salt to the amount of cetylpyridinium chloride (glycyrrhizic acid or its salt / cetylpyridinium chloride), the more significant the bactericidal activity decreases. Therefore, the composition for oral cavity having a larger mass ratio preferably exhibits the effect of suppressing the bactericidal power reduction by the components (iii) and (iv). The mass ratio (glycyrrhizic acid or a salt thereof / cetylpyridinium chloride) in the composition for oral cavity of the present invention is 1 or more, preferably 1 to 10, more preferably 1 to 5.

  The oral composition of the present invention can be produced by a conventional method, and can be used, for example, as a pharmaceutical product or a quasi drug. Particularly preferred are pharmaceuticals. Further, the form of the composition for oral cavity of the present invention is not particularly limited, but for example, an ointment, paste, pasta, gel, liquid, spray, mouthwash, liquid dentifrice, It can be in a form (dosage form) such as a toothpaste or gum. Of these, mouthwash, liquid dentifrice, toothpaste, ointment, paste, liquid, spray, and gel are preferred.

  As described above, in the oral composition of the present invention, a decrease in the bactericidal activity of cetylpyridinium chloride due to glycyrrhizic acid or a salt thereof is suppressed. Furthermore, glycyrrhizic acid or a salt thereof has an anti-inflammatory effect. Therefore, the composition for oral cavity of the present invention can be suitably used for oral care as an anti-inflammatory agent or bactericidal agent for oral cavity. In particular, it can be preferably used as a dental oral medicine such as alveolar purulent medicine for alleviation of various symptoms associated with periodontal disease, periodontitis, and / or gingivitis. Examples of the symptoms include gingival bleeding, redness, swelling, itchiness, pain, itching, or stickiness of the mouth, bad breath, and the like. It can also be preferably used for treatment and / or alleviation of stomatitis.

  In addition to the above components (i) to (iv), the oral composition of the present invention may contain any optional component that can be blended in the oral composition within a range that does not impair the effects of the present invention. You may further contain in combination.

  For example, a nonionic surfactant, an anionic surfactant or an amphoteric surfactant can be blended as the surfactant. Specifically, nonionic surfactants include sugar fatty acid esters such as sucrose fatty acid esters, maltose fatty acid esters, and lactose fatty acid esters; fatty acid alkanolamides; sorbitan fatty acid esters; fatty acid monoglycerides; A polyoxyethylene alkyl ether having an alkyl group having 13 to 15 carbon atoms; a polyoxyethylene addition coefficient of 10 to 18 and a polyoxyethylene alkyl phenyl ether having an alkyl group having 9 carbon atoms; diethyl sebacate; polyoxy Ethylene hydrogenated castor oil; fatty acid polyoxyethylene sorbitan and the like. Anionic surfactants include sulfate esters such as sodium lauryl sulfate and polyoxyethylene lauryl ether sulfate; sulfosuccinates such as sodium lauryl sulfosuccinate and sodium polyoxyethylene lauryl ether sulfosuccinate; cocoyl sarcosine sodium and lauroylmethylalanine Acyl amino acid salts such as sodium; cocoyl methyl taurine sodium and the like. Zwitterionic surfactants include betaine acetate type activators such as lauryl dimethylaminoacetic acid betaine, coconut oil fatty acid amidopropyldimethylaminoacetic acid betaine; imidazoline type such as N-cocoyl-N-carboxymethyl-N-hydroxyethylethylenediamine sodium Activating agents; amino acid type activating agents such as N-lauryldiaminoethylglycine. These surfactants can be blended alone or in combination of two or more. The compounding quantity is 0.1-5 mass% normally with respect to the composition whole quantity.

  Further, as a flavoring agent, carboxylic acid, anethole, eugenol, methyl salicylate, limonene, osimene, n-decyl alcohol, citronell, α-terpineol, methyl acetate, citronenyl acetate, methyl eugenol, cineol, linalool, ethyl linalool , Thymol, lemon oil, orange oil, sage oil, rosemary oil, cinnamon oil, perilla oil, winter green oil, clove oil, eucalyptus oil, pimento oil, d-camphor, d-borneol, fennel oil, cinnamon oil, Fragrances such as cinnamaldehyde, mint oil, and vanillin can be blended in an amount of 0.001 to 1.5% by mass based on the total amount of the composition alone or in combination of two or more.

  In addition, a sweetening agent such as sodium saccharin, acesulfame potassium, stevioside, neohesperidyl dihydrochalcone, perilartin, thaumatin, asparatylphenylalanylmethyl ester, p-methoxycinnamic aldehyde, etc., in the range from 0.01 to 1 is used. It can mix | blend the mass%.

  Furthermore, sorbitol, glycerin, polypropylene glycol, xylit, maltite, lactit, polyoxyethylene glycol, etc. can be blended alone or in combination of two or more as a wetting agent.

  As preservatives, parabens such as methylparaben, ethylparaben, propylparaben, butylparaben, sodium benzoate, phenoxyethanol, alkyldiaminoethylglycine hydrochloride and the like can be blended.

  As colorants, legal pigments such as Blue No. 1, Yellow No. 4, Red No. 202, and Green No. 3, mineral pigments such as ultramarine blue, enhanced ultramarine blue, and bitumen, and titanium oxide may be blended.

  As a pH adjuster, citric acid, phosphoric acid, malic acid, pyrophosphoric acid, lactic acid, tartaric acid, glycerophosphoric acid, acetic acid, nitric acid, or a chemically possible salt thereof, sodium hydroxide, or the like may be blended. These can be blended singly or in combination of two or more so that the pH of the composition is in the range of 4-8, preferably 5-7. The normal amount of the pH adjuster is 0.01 to 2% by weight.

  The oral composition of the present invention further includes, as a medicinal component, vitamin E such as dl-α-tocopherol acetate, tocopherol succinate or tocopherol nicotinate, an amphoteric fungicide such as dodecyldiaminoethylglycine, triclosan , Nonionic fungicides such as isopropylmethylphenol, enzymes such as dextranase, amylase, protease, mutanase, lysozyme, lytic enzyme (Litec Enzyme), alkali metal mono, such as sodium monofluorophosphate and potassium monofluorophosphate Fluorophosphates, fluorides such as sodium fluoride and stannous fluoride, tranexamic acid, epsilon aminocaproic acid, aluminum chlorohydroxyl allantoin, dihydrocholesterol, glycyrrhetinic acid, glycerophosphine Over DOO, chlorophyll, sodium chloride, Karopeputaido, allantoin, carbazochrome, hinokitiol, potassium nitrate, and Palatinit like, can be blended alone or in combination of two or more.

  In addition, alcohols, silicon, apatite, white petrolatum, paraffin, liquid paraffin, microcrystalline wax, squalane, plastibase, and the like can be added as a base.

  As described above, by using the above components (iii) and (iv) in combination, cetylpyridinium chloride and glycyrrhizic acid or a salt thereof are contained, and the mass ratio of glycyrrhizic acid or a salt thereof to cetylpyridinium chloride (glycyrrhizic acid or a salt thereof) Reduction in the bactericidal activity of cetylpyridinium chloride by glycyrrhizic acid or a salt thereof, which occurs in an oral composition having 1 or more (preferably 1 to 10) of salt / cetylpyridinium chloride, can be suppressed. Therefore, the present invention also includes a bactericidal activity reduction inhibitor for a composition containing cetylpyridinium chloride and glycyrrhizic acid or a salt thereof, comprising the components (iii) and (iv). The agent may consist only of the above components (iii) and (iv), or may be an appropriate combination of the above-described optional components and the components (iii) and (iv), for example. Good. The combination ratio of the components (iii) and (iv) can be appropriately set, but (iii) 1 to 30 parts by mass (preferably 2 to 25 parts by mass, more preferably 4 to 20 parts by mass) of the component. The component (iv) is preferably 0.01 to 2 parts by mass, more preferably 0.01 to 1 part by mass, further preferably 0.02 to 0.5 parts by mass, and 0.03 to 0.3 parts by mass. Even more preferred. Further, for example, 0.1 to 100% by mass of the agent may be the components (iii) and (iv). The agent can be produced, for example, by mixing various components by an appropriate method. As an example, there may be mentioned a method in which the component (iv) and optional components and water are added to the component (iii) and mixed as necessary.

  Furthermore, the present invention also includes a method for inhibiting glycyrrhizic acid or a salt thereof from reducing the bactericidal activity of cetylpyridinium chloride in the presence of saliva by using components (iii) and (iv). Also in this case, it is preferable that the amounts of (iii) and (iv) and (ii) glycyrrhizic acid or its salt and (i) cetylpyridinium chloride are used as described above.

  Among the methods, a composition containing a relatively large amount of glycyrrhizic acid or a salt thereof with respect to cetylpyridinium chloride (particularly a mass ratio of glycyrrhizic acid or a salt thereof with respect to cetylpyridinium chloride is 1 or more) includes the above (iii) and (Iv) The method of suppressing the bactericidal power fall of cetyl pyridinium chloride including the process of adding a component is preferable. In the method, the components (iii) and (iv) are mixed in advance and then added as a mixture containing (iii) and (iv).

  Furthermore, the present invention contains components (i) to (iv), and (ii) a mass ratio of (ii) glycyrrhizic acid or a salt thereof to cetylpyridinium chloride (glycyrrhizic acid or a salt thereof / cetylpyridinium chloride) is 1. The method for producing the composition as described above is also included. The method includes a step of mixing (i) to (iv). The amount of the components (i) and (ii) to be mixed is such that the ratio of the mass of (ii) to (i) is 1 or more. The order in which (i) to (iv) are mixed is not particularly limited except that the components (iii) and (iv) are used after being mixed in advance. That is, the method includes a step of mixing (iii) and (iv) in advance and mixing it with (i) and (ii) as a “mixture containing (iii) and (iv)”. For example, (i) and (ii) may be mixed, and “a mixture containing (iii) and (iv)” may be further mixed therewith, and a mixture containing (i) and “(iii) and (iv)” And (ii) may be further mixed, or (ii) and “mixture of (iii) and (iv)” may be mixed, and (i) may be further mixed therewith. Among these, it is more preferable to include a step of mixing the composition containing (i) and (ii) and the above-mentioned bactericidal power reduction inhibitor (preferably a mixture of (iii) and (iv)). In these methods, it is preferable that the components (i) to (iv) contained in the obtained composition satisfy various conditions such as the above-described content and mass ratio.

  The composition here is not particularly limited as long as it is applied to the oral cavity (inside), but an oral composition is preferred. Moreover, the said composition may contain the arbitrary components of the said illustration, for example.

Hereinafter, the present invention will be specifically described, but the present invention is not limited to the following examples. Hereinafter, “CPC” represents cetylpyridinium chloride, and “GK2” represents dipotassium glycyrrhizinate. In the following, “%” means “mass%” unless otherwise specified.
<Examination of bactericidal activity of a composition containing CPC>
According to the composition described in Tables 1 to 5, CPC, GK2, various alcohols (propylene glycol, 1,3-butylene glycol, ethanol, glycerin, sorbit), and l-menthol were dissolved in purified water, and various solution compositions (Embodiments, comparative examples, and reference examples: see Tables 1 to 5) were prepared. The numerical values in Tables 1 to 5 indicate amounts (mass%) in which CPC, GK2, various alcohols, and l-menthol are contained in the solution composition. Tables 4 and 5 also show values of the mass ratio of GK2 to CPC (GK2 / CPC). In the table, when each component amount is blank, it indicates that the component is not included. In addition, the mass ratio (GK2 / CPC) of GK2 and CPC in each example described in Tables 1 to 3 is 2.

In addition, Example 1-1, Example 2-4, and Example 3-3 are all the same compositions.
〔Test method〕
Preparation of Bacterial Solution Unstimulated saliva was collected from 4 healthy individuals, mixed in equal amounts and stirred uniformly. The saliva mixed solution was used as a bacterial solution (oral bacteria-containing solution) in the following examination.
Test Method 200 μL of each solution composition was dispensed into each well of a reaction plate (96-well titer plate), and 20 μL of a bacterial solution was added to each well, followed by stirring by pipetting. Thirty seconds later, 20 μL of the solution was collected from each well, added to each well of the culture plate (96-well titer plate) (100 μL of TSB / Y / VH medium was dispensed), and mixed. The same treatment was performed 1, 2, 3, 4, 5, 10, 20 minutes after the addition of the bacterial solution.

  After that, when the culture medium was left standing in an anaerobic box (Anaerobic System Model 1025: Forma Scientific) for 48 hours and the medium became turbid (visual judgment), it was assumed that the bacteria had grown and contained in the solution added to the culture plate. The bacteria were determined not to be sterilized. The determination was made for each solution collected from the reaction plate after 30 seconds and 1, 2, 3, 4, 5, 10, 20 minutes, and the bacteria did not grow for the first time (that is, the culture medium did not become turbid after culture). The time was defined as “time required for sterilization”. The results are shown in Tables 1 to 5. If it was not sterilized after 20 minutes, it was marked “ND” in the table. Moreover, when it was already sterilized after 30 seconds, it was written in the table as “within 30 seconds”.

The TSB / Y / VH medium was prepared by dissolving each component having the following composition in distilled water and autoclaving.

  From Reference Examples A to E (Table 5), it was found that CPC has an excellent sterilizing power and the sterilizing power increases in a concentration-dependent manner.

  Further, from Comparative Examples A to E and Reference Examples A to E (Table 5), when GK2 is contained in a relatively large amount with respect to CPC ((GK2 / CPC) value is 1 or more), the sterilizing power of CPC is determined by GK2. It turns out that it falls.

  Furthermore, from each Example (Table 1 to Table 4) and each Comparative Example (Table 1 to Table 5), the composition containing CPC and GK2 and having a (GK2 / CPC) value of 1 or more, further propylene glycol, It turned out that the fall of the said bactericidal power is suppressed by containing 1, 3- butylene glycol or ethanol and l-menthol. In particular, in Examples 1-1 to 1-3, 2-3 to 2-5, 3-2-3-4, and 4-1 to 4-4, the time required for sterilization is significantly shortened ( At least 3 minutes), which proved particularly favorable.

  Below, a prescription example is described. The numerical value of each component in the formulation example indicates mass%. Moreover, in the following prescription examples, pH was adjusted to 5.5-7.0 with the pH adjuster.

Claims (3)

(Ii) cetylpyridinium chloride, (ii) glycyrrhizic acid or a salt thereof, (iii) at least one alcohol selected from the group consisting of propylene glycol, 1,3-butylene glycol, and ethanol, and (iv) l- Contains menthol,
The composition for oral cavity whose mass ratio (Glycyrrhizic acid or its salt / cetylpyridinium chloride) of glycyrrhizic acid or its salt with respect to cetylpyridinium chloride is 1 or more. The composition for oral cavity of Claim 1 which contains 0.05-0.5 mass% of (i), and 0.05-0.5 mass% of (ii). The composition for oral cavity of Claim 1 or 2 which contains (iii) 1-30 mass% and (iv) 0.01-2 mass%.